These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27090436)

  • 1. Predictors of cholesterol treatment discussions and statin prescribing for primary cardiovascular disease prevention in community health centers.
    Karmali KN; Lee JY; Brown T; Persell SD
    Prev Med; 2016 Jul; 88():176-81. PubMed ID: 27090436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.
    Persell SD; Brown T; Lee JY; Shah S; Henley E; Long T; Luther S; Lloyd-Jones DM; Jean-Jacques M; Kandula NR; Sanchez T; Baker DW
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):560-6. PubMed ID: 26555123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.
    Han BH; Sutin D; Williamson JD; Davis BR; Piller LB; Pervin H; Pressel SL; Blaum CS;
    JAMA Intern Med; 2017 Jul; 177(7):955-965. PubMed ID: 28531241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.
    Pursnani A; Massaro JM; D'Agostino RB; O'Donnell CJ; Hoffmann U
    JAMA; 2015 Jul; 314(2):134-41. PubMed ID: 26172893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
    Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
    BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort.
    Bai JW; Boulet G; Halpern EM; Lovblom LE; Eldelekli D; Keenan HA; Brent M; Paul N; Bril V; Cherney DZ; Weisman A; Perkins BA
    Cardiovasc Diabetol; 2016 Jan; 15():14. PubMed ID: 26809442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study.
    Chapman RH; Petrilla AA; Berman L; Benner JS; Tang SS
    Am J Cardiovasc Drugs; 2009; 9(5):299-308. PubMed ID: 19791839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Peterson GG; Pu J; Magid DJ; Barterian L; Kranker K; Barna M; Conwell L; Rose A; Blue L; Markovitz A; McCall N; Markovich P
    JAMA Cardiol; 2021 Sep; 6(9):1050-1059. PubMed ID: 34076665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electronic health record-based patient identification and individualized mailed outreach for primary cardiovascular disease prevention: a cluster randomized trial.
    Persell SD; Lloyd-Jones DM; Friesema EM; Cooper AJ; Baker DW
    J Gen Intern Med; 2013 Apr; 28(4):554-60. PubMed ID: 23143672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
    Valentino M; Al Danaf J; Panakos A; Ragupathi L; Duffy D; Whellan D
    Am Heart J; 2016 Nov; 181():130-136. PubMed ID: 27823684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare.
    Hyun KK; Redfern J; Patel A; Peiris D; Brieger D; Sullivan D; Harris M; Usherwood T; MacMahon S; Lyford M; Woodward M
    Heart; 2017 Apr; 103(7):492-498. PubMed ID: 28249996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults.
    Ngo-Metzger Q; Gottfredson R
    Am Fam Physician; 2017 Dec; 96(12):805-806. PubMed ID: 29431375
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.